Drug/Laboratory Tests Interactions Hyperaminotransferasemia
Significant elevations of aminotransferase (SGOT [S-AST] and SGPT [S-ALT]) levels have occurred
in a high percentage of patients (and healthy subjects) who have received heparin. Since
aminotransferase determinations are important in the differential diagnosis of myocardial infarction,
liver disease and pulmonary emboli, increases that might be caused by drugs (like heparin) should be
interpreted with caution.
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term studies in animals have been performed to evaluate carcinogenic potential of heparin.
Also, no reproduction studies in animals have been performed concerning mutagenesis or impairment
of fertility.
Pregnancy Teratogenic Effects—Pregnancy Category C
Animal reproduction studies have not been conducted with heparin sodium. It is also not known
whether heparin sodium can cause fetal harm when administered to a pregnant woman or can affect
reproduction capacity. Heparin sodium should be given to a pregnant woman only if clearly needed.
Nonteratogenic Effects Heparin does not cross the placental barrier.
Nursing Mothers Heparin is not excreted in human milk.
Pediatric Use See DOSAGE AND ADMINISTRATION–Pediatric Use.
Geriatric Use A higher incidence of bleeding has been reported in patients over 60 years of age, especially women
(see PRECAUTIONS, General). Clinical studies indicate that lower doses of heparin may be
indicated in these patients (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
ADVERSE REACTIONS Hemorrhage Hemorrhage is the chief complication that may result from heparin therapy. (See WARNINGS.) An
overly prolonged clotting time or minor bleeding during therapy can usually be controlled by
withdrawing the drug. (See OVERDOSAGE.) It should be appreciated that gastrointestinal or
